Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release - PubMed (original) (raw)
. 2003 Apr 1;63(7):1712-21.
Affiliations
- PMID: 12670926
Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release
Karthikeyan Kandasamy et al. Cancer Res. 2003.
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L induces apoptosis in a wide variety of cancer and transformed cells. Activation of BID, a "BH3-domain-only" Bcl-2 family member, triggers the oligomerization of proapoptotic family members Bak or Bax, resulting in the release of mitochondrial proteins to cytosol. In this study, we have shown the importance of Bax and Bak in TRAIL-induced apoptosis by studying in murine embryonic fibroblasts (MEFs) from Bax(-/-) and Bak(-/-) animals. TRAIL induced cytochrome c release and apoptosis in wild-type, Bid(-/-), Bax(-/-), or Bak(-/-) MEFs, but not in Bax(-/-) Bak(-/-) double knockout (DKO) MEFs. Bid, which functions upstream of cytochrome c release, was cleaved in all of the knockout cells except in Bid(-/-) MEFs. The release of cytochrome c was correlated with caspase-9 activity. TRAIL increased caspase-3 activity in all of the cells except in DKO cells. TRAIL-induced drop in mitochondrial membrane potential was not observed in DKO MEFs. Unlike cytochrome c release, TRAIL-induced Smac/DIABLO release was blocked in Bid(-/-), Bax(-/-), Bak(-/-), or DKO MEFs, suggesting the differential regulation of these mitochondrial proteins during apoptosis. The apoptotic events downstream of mitochondria were intact in DKO MEFs, because microinjection of cytochrome c, or ectopic expression of mature Smac/DIABLO or pretreatment of Smac N7 peptide completely restored TRAIL sensitivity. In conclusion, the data suggest that Bax and Bak differentially regulate the release of cytochrome c and Smac/DIABLO from mitochondria, and Smac/DIABLO can be used to sensitize cells that are deficient in Bax and Bak genes, or resistant to TRAIL.
Similar articles
- Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of bax.
Jia L, Patwari Y, Kelsey SM, Newland AC. Jia L, et al. Biochem Biophys Res Commun. 2001 May 25;283(5):1037-45. doi: 10.1006/bbrc.2001.4895. Biochem Biophys Res Commun. 2001. PMID: 11355877 - Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.
Kim JY, Kim YH, Chang I, Kim S, Pak YK, Oh BH, Yagita H, Jung YK, Oh YJ, Lee MS. Kim JY, et al. Oncogene. 2002 May 9;21(20):3139-48. doi: 10.1038/sj.onc.1205406. Oncogene. 2002. PMID: 12082629 - Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
Aggarwal BB, Bhardwaj U, Takada Y. Aggarwal BB, et al. Vitam Horm. 2004;67:453-83. doi: 10.1016/S0083-6729(04)67023-3. Vitam Horm. 2004. PMID: 15110190 Review. - Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c.
Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Korsmeyer SJ, et al. Cell Death Differ. 2000 Dec;7(12):1166-73. doi: 10.1038/sj.cdd.4400783. Cell Death Differ. 2000. PMID: 11175253 Review.
Cited by
- Responses of solid tumor cells in DMEM to reactive oxygen species generated by non-thermal plasma and chemically induced ROS systems.
Kaushik N, Uddin N, Sim GB, Hong YJ, Baik KY, Kim CH, Lee SJ, Kaushik NK, Choi EH. Kaushik N, et al. Sci Rep. 2015 Feb 26;5:8587. doi: 10.1038/srep08587. Sci Rep. 2015. PMID: 25715710 Free PMC article. - Combined modality therapy with TRAIL or agonistic death receptor antibodies.
Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Amm HM, et al. Cancer Biol Ther. 2011 Mar 1;11(5):431-49. doi: 10.4161/cbt.11.5.14671. Epub 2011 Mar 1. Cancer Biol Ther. 2011. PMID: 21263219 Free PMC article. Review. - Nano-TRAIL: a promising path to cancer therapy.
Gampa SC, Garimella SV, Pandrangi S. Gampa SC, et al. Cancer Drug Resist. 2023 Feb 1;6(1):78-102. doi: 10.20517/cdr.2022.82. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37065863 Free PMC article. Review. - Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential.
Shankar S, Chen Q, Siddiqui I, Sarva K, Srivastava RK. Shankar S, et al. J Mol Signal. 2007 Aug 24;2:7. doi: 10.1186/1750-2187-2-7. J Mol Signal. 2007. PMID: 17718901 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials